In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3

Journal of Steroid Biochemistry and Molecular Biology

Volumn 141, Issue , 2014, Pages 44-51

  Roy, Jenny ^a   Fournier, Michelle Audrey ^a   Maltais, René ^a   Kenmogne, Lucie Carolle ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 Hydroxysteroid dehydrogenase; Androgen; Enzyme; Hormone; Inhibitor; Prostate cancer; Steroid

Indexed keywords

17 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3; ANDROSTERONE DERIVATIVE; RM 532 105; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; ENZYMATIC ASSAY; FEEDING; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROSTATE; PROSTATE CANCER; PROSTATE WEIGHT; PROTEIN EXPRESSION; RAT; SEMINAL VESICLE; STEROID BLOOD LEVEL; TESTIS; TESTIS WEIGHT;

17Β-HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ENZYME; HORMONE; INHIBITOR; PROSTATE CANCER; STEROID;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROSTANES; ANDROSTENEDIONE; ANIMALS; DIHYDROTESTOSTERONE; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUTEINIZING HORMONE; MALE; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TESTIS; TESTOSTERONE;

EID: 84893451149     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.12.019     Document Type: Article

References (45)

1. R. Siegel, D. Naishadham, and A. Jamal Cancer Statistics 2012 CA Cancer J. Clin. 62 2012 10 29
2. J.D. McConnell Physiologic basis of endocrine therapy for prostatic cancer Urol. Clin. North Am. 18 1991 1 13
3. F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez, and B. Candas Gonadotropin-releasing hormone agonists in the treatment of prostate cancer Endocr. Rev. 26 2005 361 379 (Pubitemid 40686649)
4. F. Labrie Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support Prostate 40 2000 215 222 (Pubitemid 30230457)
5. F. Labrie, L. Cusan, C. Labrie, J. Simard, V. Luu-The, P. Diamond, F. Gomez, and B. Candas History of LHRH agonist and combination therapy in prostate cancer Endocr. Relat. Cancer 3 1996 243 278 (Pubitemid 26367780)
6. E.L. Gheiler, and R. Tiguert Current concepts in androgen deprivation therapy - is there a best endocrine treatment? World J. Urol. 18 2000 190 193
7. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J. Urol. 164 2000 726 729 (Pubitemid 30637611)
8. M.G. Oefelein Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment Urology 54 1999 694 699 (Pubitemid 29449432)
9. J. Simard, I. Luthy, J. Guay, A. Bélanger, and F. Labrie Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues Mol. Cell. Endocrinol. 44 1986 261 270 (Pubitemid 16165779)
10. D. Poirier New cancer drugs targeting the biosynthesis of estrogens and androgens Drug Dev. Res. 69 2008 304 318
11. G. Moeller, and J. Adamski Integrated view on 17beta-hydroxysteroid dehydrogenases Mol. Cell. Endocrinol. 301 2009 7 19
12. S. Marchais-Oberwinkler, C. Henn, G. Möller, T. Klein, M. Negri, A. Oster, A. Spadaro, R. Werth, M. Wetzel, K. Xu, M. Frotscher, R.W. Hartmann, and J. Adamski 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development J. Steroid Biochem. Mol. Biol. 125 2011 66 82
13. V. Luu-The, and F. Labrie The intracrine sex steroid biosynthesis pathways L. Martini, Progress in Brain Research 181 2010 177 192 (Chap. 10)
14. F. Labrie, V. Luu-The, S.X. Lin, C. Labrie, J. Simard, R. Breton, and A. Bélanger The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology Steroids 62 1997 148 158 (Pubitemid 27066999)
15. M. Rotinen, J. Villar, and I. Encio Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage J. Physiol. Biochem. 68 2012 461 473
16. F. Labrie, V. Luu-The, C. Labrie, A. Bélanger, J. Simard, S.X. Lin, and G. Pelletier Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone Endrocr. Rev. 24 2003 152 182 (Pubitemid 36515283)
17. Y. Laplante, and D. Poirier Proliferative effect of androst-4-ene-3,17- dione and its metabolites in the androgen-sensitive LNCaP cell line Steroids 73 2008 266 271
18. T.M. Penning Molecular endocrinology of hydroxysteroid dehydrogenases Endocr. Rev. 18 1997 281 305 (Pubitemid 27246879)
19. M.L. Mohler, R. Narayanan, Y. He, D.D. Miller, and J.T. Dalton Hydroxysteroid dehydrogenase (17β-HSD3, 17β-HSD5, and 3α-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels Recent Patents Endocr. Metab. Immune Drug Discov. 1 2007 103 118
20. W.M. Geissler, D.L. Davis, L. Wu, K.D. Bradshaw, S. Patel, B.B. Mendoca, K.O. Elliston, J.D. Wilson, D.W. Russell, and S. Andersson Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3 Nat. Genet. 7 1994 34 39
21. S. Andersson, W.M. Geissler, S. Patel, and L. Wu The molecular biology of androgenic 17β-hydroxysteroid dehydrogenases J. Steroid Biochem. Mol. Biol. 53 1995 37 39
22. E. Koh, T. Noda, J. Kanaya, and M. Namiki Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues Prostate 53 2002 154 159
23. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
24. J.A. Locke, E. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res. 68 2008 6407 6415
25. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P. Nelson Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Res. 67 2007 5033 5041 (Pubitemid 46910214)
26. M. Biancolella, A. Valentini, D. Minella, L. Vecchione, F. D'Amico, G. Chillemi, P. Gravina, S. Bueno, G. Prosperini, A. Desideri, G. Federici, S. Bernardini, and G. Novelli Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines Invest. New Drugs 25 2007 491 497 (Pubitemid 47222914)
27. I. Dufort, P. Rheault, X.F. Huang, and P. Soucy Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase Endocrinology 140 1999 568 574 (Pubitemid 29058186)
28. M.C. Byrns, Y.T. Jin, and T.M. Penning Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 125 2011 95 114
29. V. Luu-The, A. Bélanger, and F. Labrie Androgen biosynthetic pathways in the human prostate Best Pract. Res. Clin. Endocrinol. Metab. 22 2008 207 221 (Pubitemid 351611954)
30. V. Luu-The Assessment of steroidogenesis and steroidogenic enzyme functions J. Steroid Biochem. Mol. Biol. 137 2013 176 182
31. J.L. Mohler, M.A. Titus, and E.M. Wilson Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone Clin. Cancer Res. 17 2011 5844 5849
32. N. Sharifi, and R.J. Auchus Steroid biosynthesis and prostate cancer Steroids 77 2012 719 726
33. D. Poirier 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review Exp. Opin. Ther. Patents 20 2010 1123 1145
34. J.M. Day, H.J. Tutill, A. Purohit, and M.J. Reed Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer 15 2008 665 692
35. + cell lines Mol. Cell. Endocrinol. 248 2006 225 232
36. B. Tchédam-Ngatcha, V. Luu-The, F. Labrie, and D. Poirier Androsterone 3α-ether-3β-substituted and androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship J. Med. Chem. 48 2005 5257 5268 (Pubitemid 41113912)
37. R. Maltais, V. Luu-The, and D. Poirier Synthesis and optimization of a new family of type 3 17 β-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry J. Med. Chem. 45 2002 640 653 (Pubitemid 34145710)
38. R. Maltais, M.A. Fournier, and D. Poirier Development of 3β-substituted androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3 Bioorg. Med. Chem. 19 2011 4652 4668
39. V. Luu-The, Y. Zhang, D. Poirier, and F. Labrie Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition J. Steroid Biochem. Mol. Biol. 55 1995 581 587 (Pubitemid 26019342)
40. F. Labrie, A. Bélanger, P. Bélanger, R. Bérubé, C. Martel, L. cusan, J. Gomez, B. Candas, V. Chaussade, I. Castiel, C. Deloche, and J. Leclaire Metabolism of DHEA in postmenopausal women following percutaneous administration J. Steroid Biochem. Mol. Biol. 103 2007 178 188 (Pubitemid 46157181)
41. M.M. Bradford A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
42. C.Y. Kramer Extension of multiple range tests to group with unique numbers of replications Biometrics 12 1956 307 310
43. H. Peltoketo, V. Luu-The, J. Simard, and J. Adamski 17β- Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes J. Mol. Endocrinol. 23 1999 1 11 (Pubitemid 29369554)
44. P.E. Juniewicz, B.H. Johnson, and D.J. Bolt Effect of adrenal steroid on testosterone and luteinizing hormone secretion in the ram J. Androl. 30 1987 190 196 (Pubitemid 17110752)
45. G. Attard, A.S. Belldegrun, and J.S. De Bono Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer BJU Int. 96 2005 1241 1246 (Pubitemid 41743917)